



US006770628B2

(12) **United States Patent**  
Wallner et al.

(10) **Patent No.:** US 6,770,628 B2  
(45) **Date of Patent:** \*Aug. 3, 2004

(54) **HEMATOPOIETIC STIMULATION**

(75) Inventors: **Barbara P. Wallner**, Weston, MA (US); **Barry Jones**, Cambridge, MA (US); **Glenn T. Miller**, Haverhill, MA (US); **Sharlene Adams**, Watertown, MA (US)

(73) Assignee: **Point Therapeutics, Inc.**, Boston, MA (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **09/878,792**

(22) Filed: **Jun. 11, 2001**

(65) **Prior Publication Data**

US 2002/0013279 A1 Jan. 31, 2002

**Related U.S. Application Data**

(62) Division of application No. 09/304,199, filed on May 3, 1999, now Pat. No. 6,300,314.

(60) Provisional application No. 60/084,128, filed on May 4, 1998.

(51) **Int. Cl.**<sup>7</sup> ..... **A61K 38/04**; A61K 38/05; A61K 38/16

(52) **U.S. Cl.** ..... **514/19**; 514/13; 514/14; 514/15; 514/16; 514/17; 514/18; 514/423

(58) **Field of Search** ..... 514/13, 14, 15, 514/16, 17, 18, 19, 20, 423; 435/70.3, 70.4, 70.5, 372, 372.1, 372.2, 372.3, 405, 406

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,318,904 A 3/1982 Shaw et al. .... 424/177  
4,443,609 A 4/1984 Oude Alink et al. .... 548/111

(List continued on next page.)

**FOREIGN PATENT DOCUMENTS**

DD 158109 12/1982  
DD 270382 A1 7/1989

(List continued on next page.)

**OTHER PUBLICATIONS**

Colowick, S., et al., "Methods in Enzymology", pp. 220-225, vol. XLVI, (Not dated).

(List continued on next page.)


*Primary Examiner*—Jeffrey E. Russel

(74) *Attorney, Agent, or Firm*—Wolf, Greenfield and Sacks, P.C.

(57) **ABSTRACT**


Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I:

Formula I



wherein m is an integer between 0 and 10, inclusive; A and A<sub>1</sub> are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A<sub>1</sub> and C, and between A<sub>1</sub> and N are peptide bonds; and each X<sub>1</sub> and X<sub>2</sub> is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. A particularly preferred agent that is useful in practicing the invention is a ValBoroPro.

**21 Claims, 6 Drawing Sheets**



## U.S. PATENT DOCUMENTS

4,499,082	A	2/1985	Shenvi et al. ....	514/2
4,582,821	A	4/1986	Kettner et al. ....	514/18
4,636,492	A	1/1987	Kettner et al. ....	514/18
4,644,055	A	2/1987	Kettner et al. ....	530/330
4,652,552	A	3/1987	Kettner et al. ....	514/18
4,935,493	A	6/1990	Bachovchin et al. ....	530/331
4,963,655	A	10/1990	Kinder et al. ....	530/331
5,093,477	A	3/1992	Mölling et al. ....	530/328
5,187,157	A	2/1993	Kettner et al. ....	514/18
5,215,926	A	6/1993	Etchells, III et al. ....	436/501
5,242,904	A	9/1993	Kettner et al. ....	514/18
5,250,720	A	10/1993	Kettner et al. ....	558/288
5,288,707	A	2/1994	Metternich ....	514/19
5,296,604	A	3/1994	Hanko et al. ....	546/169
5,329,028	A	7/1994	Ashkenzi et al. ....	548/548
5,378,624	A	1/1995	Berenson et al. ....	435/239
5,384,410	A	1/1995	Kettner ....	548/405
5,444,049	A	8/1995	de Nanteuil et al. ....	514/18
5,462,928	A	10/1995	Bachovchin et al. ....	514/19
5,506,130	A	4/1996	Peterson et al. ....	435/240.1
5,527,923	A	6/1996	Klingler et al. ....	548/570
5,543,396	A	8/1996	Powers et al. ....	514/19
5,554,728	A	9/1996	Basava et al. ....	530/327
5,635,386	A	6/1997	Palsson et al. ....	435/372
5,635,387	A	6/1997	Fei et al. ....	435/378
5,646,043	A	7/1997	Emerson et al. ....	435/373
6,040,145	A *	3/2000	Huber et al. ....	435/7.2
6,100,234	A *	8/2000	Huber et al. ....	514/2
6,258,597	B1	7/2001	Bachovchin et al. ....	435/325
6,300,314	B1 *	10/2001	Wallner et al. ....	514/19

## FOREIGN PATENT DOCUMENTS

DD	296075	A5	11/1991
EP	0356223	A2	2/1990
EP	0371467	A2	6/1990
EP	0471651	A2	2/1992
EP	0481311	A2	4/1992
EP	0615978	A1	9/1994
EP	0420913	B1	11/1995
EP	0688788	A1	12/1995
WO	WO 89/03223		4/1989
WO	WO 91/16339		10/1991
WO	WO 91/17767		11/1991
WO	WO 92/12140		7/1992
WO	WO 92/17490		10/1992
WO	WO 93/02057		2/1993
WO	WO 93/05011		3/1993
WO	WO 93/08259		4/1993
WO	WO 93/10127		5/1993
WO	WO 93/16102		8/1993
WO	WO 94/03055		2/1994
WO	WO 94/09132		4/1994
WO	WO 94/20526		9/1994
WO	WO 94/25873		11/1994
WO	WO 94/28915		12/1994
WO	WO 94/29335		12/1994
WO	WO 95/11689		5/1995
WO	WO 95/12618		5/1995
WO	WO 95/15309		6/1995
WO	WO 95/29190		11/1995
WO	WO 95/29691		11/1995
WO	WO 95/34538		12/1995
WO	WO 96/40263		12/1996
WO	WO 96/40858		12/1996
WO	WO 98/00439		1/1998
WO	WO 98/50046		11/1998

## OTHER PUBLICATIONS

- Cordes, E., et al., "Transition States for Hydrolysis of Acetals, Ketals Glycosides, and Glycosylamines", Chapter 11, pp. 429–465, (Not dated).
- Thompson, R., "Use of Peptide Aldehydes to Generate Transition-State Analogs of Elastase", *Biochemistry*, (1973), 12:1:47–51.
- Baugh, R., et al., "Proteinase and Tumor Invasion", (1980), 165:157–179.
- Bodanszky, M., "Principles of Peptide Synthesis", Springer-Verlag, (1984), vol. 16.
- Bodanszky, M., "The Practice of Peptide Synthesis", Springer-Verlag, (1984), vol. 21.
- Matteson, D., et al., "Synthesis and Properties of Pinanediol—AM IDO Boronic Esters" *Organometallics*, (1984), 3:1284–1288.
- Powers, C., et al., "Elastase Inhibitors for Treatment of Emphysema—NHLBI Workshop Summary", *U.S. Dept. of Health and Human Services*, (1985), 1097–1100.
- Yoshimoto, T., et al., "Comparison of Inhibitory Effects of Proline-Containing Peptide Derivatives on Prolyl . . .", (1985), 98:975–979.
- Kettner, C.A., et al., "Kinetic Properties of the Binding of Alpha-Lytic Protease to Peptide Boronic Acids", *Biochemistry*, (1988), 27:7682–7688.
- Tam, J.P., "Synthetic Peptide Vaccine Design: Synthesis and Properties of a High-Density Multiple Antigenic Peptide System", *Proc Natl Acad Sci U S A*, (1988), 85:5409–5413.
- Bailey, P.D., "An Introduction to Peptide Chemistry", *Wiley Publishers*, (1990), 1–81.
- Kettner, C.A. and Shenvi, A.B., "Peptide Boronic Acid Inhibitors of Trypsin-Like Proteases, Their Preparation and Use as Coagulants and Inflammation Inhibitors", *Chemical Abstracts Onlys*, (1990), 112:80 (91790c).
- Bachovchin, W.W., et al., "Inhibition of IGA1 Proteinase from *Neisseria Gonorrhoeae* and *Hemophilus Influenzae* by Peptide Prolyl Boronic Acids", *J. Biol. Chem.*, (1990), 265:3738–3743.
- Kinder D.H., et al., "Analogues of Carbamyl Aspartate as Inhibitors of Dihydroorotase Preparation of Boronic Acid Transition-State Analogues and a Zinc Chelator Carbamyl-homocysteine", *Carbamylhomocysteine, J. Med. Chem.*, (1990), 33:819–823.
- Flentke, G.R., et al., "Inhibition of Dipeptidyl Aminopeptidase IV (DP-IV) by XAA-Boropro Dipeptides and Use of These Inhibitors to Examine the Role of DP-IV in T-Cell Function", *Proc Natl Acad Sci U S A*, (1991), 88:1556–1559.
- Schon, E., et al., "Dipeptidyl Peptidase IV in the Immune System", *Biol Chem Hoppe-Seyler*, (1991), 372:305–311.
- Kubota, T., et al., "Involvement of Dipeptidyl Peptidase IV in an in Vivo Immune Response", *Clin Exp Immunol*, (1992), 89:192–197.
- Kelly, T.A., et al., "Immunosuppressive Boronic Acid Dipeptides: Correlation Between Conformation and Activity", *J Am Chem Soc*, (1993), 115:12637–12638.
- Songyang, Z., et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences", *Cell*, (1993), 72:767–778.
- Subramanyam, M., et al., "Mechanism of HIV-1 TAT Induced Inhibition of Antigen-Specific T Cell Responsiveness", *J Immunol*, (1993), 150:2544–2553.
- Demuth, H.U. et al., "Design of (Omega-N-(O-ACYL)Hydroxy AMID) Aminodicarboxylic Acid Pyrrolidides as

- Janeway, C., et al., "Immunobiology—The Immune System in Health and Disease", *Current Biology LTD*, (1994), Chapter 12, pp. 1–35.
- Brady, L., and Dodson, G., "Reflections on a Peptide", *Nature*, (1994), 368:692–693.
- Nicola, N, et al., "Guidebook to Cytokines and Their Receptors", Sambrook and Tooze Publication, (1994), pp. 1–257. Perstorp Biotec Company, "Molecular Biology Catalog", (1994).
- Jameson, B.A., et al., "A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis", *Nature*, (1994), 368:744–746—Abstract Only.
- Mosmann, T.R., "Cytokine Patterns During the Progression to Aids", *Science*, (1994), 265:193–194.
- Seed, B., "Making Agonists of Antagonists", *Chemistry & Biology*, (1994), 1:125–129.
- Austin, D.J., et al., "Proximity Versus Allosteric: The Role of Regulated Protein Dimerization in Biology", *Chemistry & Biology*, (1994), 1:131–136.
- Sudmeier, J.L., et al., "Solutions Structures of Active and Inactive Forms of the DP IV (CD26) Inhibitor Pro-Boropro Determined by NMR Spectroscopy", *Biochemistry*, (1994), 33:12427–12438.
- Kubota, T., et al., "Dipeptidyl Peptidase (DP IV) Activity in Serum and on Lymphocytes of MRL–/Mp–lpr/lpr Mice Correlates with Disease Onset", *Clin Exp Immunol*, (1994), 96:292–296.
- Snow, R.J., et al., "Studies on Proline Boronic Acid Dipeptide Inhibitors of Dipeptidyl Peptidase IV: Identification of a Cyclic Species Containing a B–N Bond", *J. Am. Chem. Soc*, (1994), 116:10860–10869.
- Günther, U.L., et al., "Solution Structures of the DP IV (CD26) Inhibitor Val–BoroPro Determined by NMR Spectroscopy", *Magnetic Resonance in Chem*, (1995), 33:959–970.
- Subramanyam, M., et al., "CD26, AT–Cell Accessory Molecule Induction of Antigen–Specific Immune–Suppression by Inactivation of CD26: A Clue to the AIDS Paradox?", in *Dipeptidyl Peptidase IV(CD26) in Metabolism and Immune Response*, (1995), Ed. B. Fleischer: 155–162.
- Schmitz T, et al., "Potentiation of the Immune Response in HIV–1+Individuals", *J Clin Invest*, (1996), 97:1545–1549.
- Aguila, H.L., et al., "From Stem Cells to Lymphocytes: Biology and Transplantation", *Immun Rev*, (1997), 157:13–40.
- Dupont, B., "Immunology of Hematopoietic Stem Cell Transplantation: A Brief Review of its History", *Immun Rev*, (1997), 157:5–12.
- Bodansky, M., "Peptide Chemistry, A Practical Textbook", Springer–Verlag, (1988) 1–9.
- Boros, L.G., et al., "Fluoroolefin Peptide Isosteres—Tools for Controlling Peptide Conformations", *Tetrahedron Letters*, (1994), 35:6033–6036.
- Goodman, M., and Chorev, M., "On the Concept of Linear Modified Retro–Peptide Structures", *Accounts of Chemical Research*, (1979), 12:1–7.
- Guichard, G., et al., Partially Modified Retro–Inverso Pseudopeptides as Non–Natural Ligands for the Human Class I Histocompatibility Molecule HLA–A2, *J Med Chem*, (1996), 39:2030–2039.
- Jardetzky, T.S., et al., Three–Dimensional Structure of a Zimmerman, D.H., et al., "A New Approach to T–Cell Activation: Natural and Synthetic Conjugates Capable of Activating T Cells", *Vaccine Res*, (1996), 5:91–102.
- Zimmerman, D.H., et al., "Immunization with Peptide Heteroconjugates Primes A T Helper Cell . . ." *Vaccine Res*, (1996), 5:103–118.
- Welch, J.T., and Lin J., Fluoroolefin Containing Dipeptide Isosteres as Inhibitors of Dipeptidyl Peptidase IV (CD26), *Tetrahedron*, (1995), 52:291–304.
- Duke–Cohan, J.S., et al., "Targeting of an Activated T–Cell Subset Using a Bispecific Antibody–Toxin Conjugate Directed Against CD4 and CD26", *Blood*, (1993), 82:2224–2234. (Abstract only) directed against CD4 and CD26. *Blood*. Oct. 1, 1993; 82(7):2224–2234.
- Kameoka, J., et al., "Direct Association of Adenosine Deaminase with a T Cell Activation Antigen, CD26", *Science*, (1993), 261:466–469. (Abstract only).
- Hegen, M., et al., "Function of Dipeptidyl Peptidase IV (CD26, TP103) in Transfected Human T Cells", *Cell Immunol*, (1993), 146:249–260. (Abstract only).
- Hegen, M., et al., "Enzymatic Activity of CD26 (Dipeptidyl Peptidase IV) is not Required for its Signalling Function in T Cells", *Immunobiology*, (1993), 189:483–493. (Abstract only).
- Tanaka, T., et al., "The Costimulatory Activity of the CD26 Antigen Requires Dipeptidyl Peptidase IV Enzymatic Activity", *Proc Natl Acad Sci U S A*, (1993), 90:4586–4590. (Abstract only).
- Tanaka, T., et al., "Cloning and Functional Expression of the T Cell Activation Antigen CD26", *J Immunol*, (1992), 149:481–486 (Abstract only).
- Scharpe, S., et al., "Purified and Cell–Bound CD26: Enzymatic Inhibition, Antibody Binding Profile, and Expression on T Cells in Relation to Other Markers", *Verh K Acad Geneesk Belg*, (1994), 56:537–559. (Abstract only).
- Kameoka J., et al., "Differential CD26–Mediated Activation of the CD3 and CD2 Pathways After CD6–Depleted Allogeneic Bone Marrow Transplantation", *Blood*, (1995), 85:1132–1137. (Abstract only).
- Mittrucker, H.W., et al., "The Cytoplasmic Tail of the T Cell Receptor ZETA Chain is Required for Signaling Via CD26", *Eur J Immunol*, (1995), 25:295–297. (Abstract only).
- Morimoto, C., et al., 1F7 "A Novel Cell Surface Molecule, Involved In Helper Function Of CD4 cells", *J. Of Immunol*. 143:34030–3439 (1989) and published erratum appears in *J. Immunology* 144 (5):2027 (Mar. 1990). Abstract only.
- Barton, R. W.J., et al., "Binding Of The T Cell Activation Monoclonal Ta1 to Dipeptidyl Peptidase IV", *Leukocyte Biology* 48:291–296 (1990). Abstract *J. Of Leukocyte Biology* 48:291–296 (1990). (Abstract only).
- Bristol, L.A., et al., "Thymocyte Costimulating Antigen Is CD26 (Dipeptidyl–Peptidase IV), Co–stimulation Of Granulocyte, Macrophage, T Lineage Cell Proliferation Via CD26", *J. Of Immunol*. 149:367–372 (1992). Abstract only.
- Bristol, L.A., et al., "Characterization Of A Novel Rat Thymocyte Costimulating Antigen By The Monoclonal Antibody 1.3", *J. Of Immunol*. 148:332–338 (1992). Abstract Only).
- Fleisher, B., et al., "Triggering Of Cytotoxic T Lymphocytes And NK Cells Via The Tp103 Pathway Is FIFf Dependent

- Hegen, M., et al., "The T Cell Triggering Molecule bx;1Tp103 . . ." *J. Immunol.* 144:2980-2914 (1990). Abstract only.
- Darmoul, D., et al., "Dipeptidyl Peptidase IV (CD26) Gene Expression In Enterocyte-like Colon Cancer Cell Lines HT-29 And Caco-2: Cloning Of The Complete Human Coding Sequence And Changes Of Dipeptidyl Peptidase IV mRNA levels During Cell Differentiation," *J. Of Biological Chemistry* 267:220-2208 (1992). Abstract only.
- Tanaka, T., et al., "Cloning And Functional Expression Of The T Cell Activation Antigen CD26", *J. Of Immunol.* 149: 481-486 (1992); published erratum appears in *J. Immunol.* 50(5): 2090 (Mar. 1993). Abstract only.
- Heins, J., et al., "Mechanism Of Proline-Specific Proteinases: (1) Substrate Specificity of Dipeptidyl Peptidase IV From Pig Kidney And Proline-Specific Endopeptidase From *Flavobacterium Meningosepticum*", *Biochimica Et Biophysica Acta* 954:161-169 (1988). Abstract only.
- Schon, E., et al., "Dipeptidyl Peptidase IV In The Immune System. Effects of Specific Enzyme Inhibitors On Activity Of Dipeptidyl Peptidase IV and Proliferation Of Human Lymphocytes", *Biological Chemistry Hoppe Seyler* 372:305-311 (1991). Abstract only.
- Schon, E., et al., "The Dipeptidyl Peptidase IV, A Membrane Enzyme Involved In The Proliferation . . . Lymphocytes", *Biomedica Biochimica Acta* 44 (1985). Abstract only.
- Schon, E., et al., "Dipeptidyl Peptidase IV in Human Lymphocytes. An Approach To The Role Of A Membrane Peptidase In The Immune System", *Biomedica Biochimica Acta* 45:1523-1528 (1986) Abstract only.
- Schon, E., et al., "The Role Of Dipeptidyl Peptidase IV in Human T Lymphocyte Activation. Inhibitors And Antibodies Against Dipeptidyl Peptidase IV Suppress Lymphocyte Proliferation And Immunoglobulin Synthesis In Vitro", *Eur. J. Of Immunol.* 17:1821-1826 (1987). Abstract only.
- Freeman, et al., "*Clinical & Experimental Immunology*" 88 (2): 275-279 (May 1992). Abstract only.
- Perry, et al., *Eur. J. Of Immunol.* 26 (1): 136-141 (Jan. 1996). Abstract only.
- Goodstone, et al., *Annals Of The Rheumatic Diseases* 55 (1):40-46 (Jan. 1996). Abstract only.
- Hall, et al., *Seminars In Dermatology*, 10 (3):240-245 (Sep. 1991). Abstract only.
- Karges, et al., *Molecular Aspects Of Medicine* 16(2):29-213 (1995). Abstract only.
- Short, et al., *Nephrol Dial Transplant* (Supp. 1) pp. 1-121 (1992). Abstract only.
- Kalluri, et al., *J. Of The American Society Of Nephrology* 6 (4):1178-1185 (Oct. 1995). Abstract only.
- Mullins, et al., *J. Of Clinical Investigation* 96 (1): 30-37 (Jul. 1996). Abstract only.
- El Far, et al., *J. Of Neurochemistry*, 64 (4): 1696-1702 (Apr. 1995). Abstract only.
- James, et al., *Clinical & Experimental Rheumatology*, 13 (3):299-305 (May-Jun. 1995). Abstract only.
- Van Noort, et al., *Nature* 375 (6534):798-801 (Jun. 29, 1995). Abstract only.
- Protti, et al., *Immunol. Today* 14 (7): 363-368 Jul. 1993). Abstract only.
- Linington, et al., *Eur. J. Of Immunol.* 22 (7): 1813-1817 (Jul. 1992). Abstract only.
- Liu, et al., *J. Of Immunol.* 155 (11): 5449-5454 (Dec. 1995). Abstract only.
- Uibo, et al., *J. Of Autoimmunity* 7 (3): 399-411 (Jun. 1994). Abstract only.
- Kokawa, et al., *Eur. J. Of Hematology* 50 (2): 74-80 (1993). Abstract only.
- Daw, et al., *J. Of Immunol.* 156 (2): 818-825 (Jan. 15, 1996). Abstract only.
- Chazenblak, et al., *J. Of Clinical Investigation* 92 (1):62-74 (Jul. 1993). Abstract only.
- Hart, et al., *Pharmaceutical Biotechnology* 6:821-845 (1995). Abstract only.
- Lopez, et al., *Vaccine* 12 (7):585-591 (1994). Abstract only.
- Reynolds, et al., *J. Of Immunol.* 152 (1):193-200 (Jan. 1, 1994). Abstract only.
- Nardelli, et al., *J. Of Immunol.* 148 (3): 914-920 (Feb. 1, 1992). Abstract only.
- Darcy, et al., *J. Of Immunol.* 149 (11):3636-3641 (Dec. 1, 1992). Abstract only.
- Ritu, et al., *Vaccine* 10 (11): 761-765 (1992). Abstract only.
- Ikagawa, et al., *J. Of Allergy & Clinical Immunol.* 97 (1 Pt 1): 53-64 (Jan. 1996). Abstract only.
- Brander, et al., *J. Of Immunol.* 155 (5):2670-2678 (Sep. 1, 1995). Abstract only.
- O'Brien, et al., *Immunology* 86 (2):176-182 (Oct. 1995). Abstract only.
- Zhu et al., *J. Immunol* 155(10), pp. 5064-5073 (Nov. 1995). Abstract only.
- Dudler, et al., *Eur. J. Of Immunol.* 25 (2):538-542 (Feb. 1995). Abstract only.
- Bungy, et al., *Eur. J. Of Immunol.* 24 (9):2098-2103 (Sep. 1994). Abstract only.
- Shimojo, et al., *Int'l. Archives Of Allergy & Immunol.* 105 (2): 155-161 (Oct. 1994). Abstract only.
- Kelly, T.A., et al., "The Efficient Synthesis And Simple Resolution Of A Proline Boronate Ester Suitable For Enzyme Inhibition Studies", *Tetrahedron* 49:1009-1016 (1993). Abstract only.
- Watson, J.D., "Continuous Proliferation Of Murine Antigen Specific Helper T Lymphocytes In Culture", *J. Of Experimental Medicine* 150:1510 (1979). Abstract only.
- Kuchroo, V.K., et al., "Induction Of Experimental Allergic Encephalomyelitis By Myelin Proteolipid-Protein-Specific T Cell Clones And Synthetic Peptides", *Pathobiology* 59:305-312 (1991). Abstract only.
- Kuchroo, V.K., et al., "T-cell Receptor Alpha Chain Plays a Critical Role In Antigen-Specific Suppressor Cell Function", *Proceedings Of The Nat'l. Academy Of Sciences Of The United States Of America* 88:8700-8704 (1991). Abstract only.
- Kuchroo, V.K., et al., "Experimental Allergic Encephalomyelitis Medicated Cloned T Cells Specific For a Synthetic Peptide of Myelin Proteolipid Protein. Fine Specificity And T Cell Receptor V Usage", *J. Of Immunol.* 148:3776-3782 (1992). Abstract only.
- Kuchroo, V.K., et al., "Cytokines And Adhesion Molecules Contribute To The Ability Of Myelin Proteolipid Protein-Specific T Cell Clones To Mediate Experimental Allergic

- Kuchroo, V.K., et al., "T Cell Receptor (TCR) Usage Determines Disease Susceptibility In Experimental Autoimmune Encephalomyelitis: Studies with TCR V Beta \* 2 Transgenic Mice", *J. Of Experimental Medicine* 179:1659-1664 (1994). Abstract only.
- Kuchroo, V.K., et al., "A Single TCR Antagonist Peptide Inhibits Experimental Allergic Encephalomyelitis Mediated By A Diverse T Cell Repertoire", *J. Of Immunol.* 153:3326-3336 (1994). Abstract only.
- Jorgensen, J.L., et al., "Molecular Components Of T-Cell Recognition," *Ann. Rev. Immunol.* 10:835-873 (1992). Abstract only.
- Wyse-Coray, T., et al., "Use Of Antibody/Peptides Constructs Of Direct Antigenic Peptides To T Cells: Evidence For T Cells Processing And Presentation", *Cellular Immunol.* 139 (1):268-73 (1992). Abstract only.
- Panina-Bordignon, P., et al., "University Immunogenic T Cell Epitopes: Promiscuous Binding To Human MHC Class II And Promiscuous Recognition By T Cells", *Eur. J. Immunol.* 19:2237-2242 (1989). Abstract only.
- Ebenbichler, C., et al., "Structure-function Relationships Of The HIV-1 Envelope V3 Loop Tropism Determinant: Evidence For Two Distinct Conformations", *Aids* 7:639-46 (1993). Abstract only.
- Linsley, P.S., et al., "Effects Of Anti-gp120 Monoclonal Antibodies On CD4 Receptor Binding By The Env Protein Of Human Immunodeficiency Virus Type 1", *J. Of Virology* 62:3695-3702 (1988). Abstract only.
- Rini, J.M., et al., "Crystal Structure Of A Human Immunodeficiency Virus Type 1 Neutralizing Antibody, 50.1, In Complex With Its V3 Loop Peptide Antigen", *Proceedings Of The Nat'l. Academy of Sciences Of The United States Of America* 90:6325-9 (1993). Abstract only.
- Subramanyam, W.G., et al., "Mechanism Of HIV-1 Tat Induced Inhibition Of Antigen-Specific T Cell Responsiveness", *J. Of Immunol.* 150:2544-2553 (1993), Abstract only.
- Dang, N.H., et al., "Cell Surface Modulation Of CD26 By Anti-1F7 Monoclonal Antibody: Analysis Of Surface Expression And Human T Cell Activation", *J. Of Immunol.* 145:3963-3971 (1990). Abstract only.
- De Caestecker, M.P., et al., "The Detection Of Intercytoplasmic Interleukin 1 (Alpha) Expression In Human Monocytes Using Two Colour Immunofluorescence Flow Cytometry", *J. Immunol. Methods* 154:11-20 (1992). Abstract only.
- Fauci, A.S., "The Human Immunodeficiency Virus: Infectivity And Mechanisms Of Pathogenesis", *Science* 239:617-722 (1988). Abstract only.
- Kinder, D., et al., "Analogues of Carbamyl Aspartate as Inhibitors . . ." *J. Med. Chem.* (1990), 33:819-823.
- Snow, R., et al., "Studies on Proline Boronic Acid Dipeptide Inhibitors of Dipeptidyl . . ." *J. Med. Chem.* (1990), 116:10860-10869.
- Wijdenes et al., "Monoclonal Antibodies (mAb) against gp130 Imitating Cytokines Which Use the gp130 for Signal Transduction", (Jul. 1995), p. 303.
- Blumenstein et al., "Synthetic Non-Peptide Inhibitors of HIV Protease," vol. 163, No. 2 (1989), pp. 980-987.
- Luftig et al., "Update on Viral Pathogenesis," *ASM News* (1990) vol. 56, No. 7, pp. 366-368.
- Jiang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Infection in a T-Cell Line (CEM) by New Dipeptidyl-Peptides IV (CD26) Inhibitors," *Res. Virol.* (1997), vol. 148, pp. 255-266.
- Coutts et al., "Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV, 1. Variation of the P<sub>2</sub> Position of X<sub>22</sub>-boroPro Dipeptides," *J. Med. Chem.* (1996), vol. 39, pp. 2087-2094.
- Ostresh et al., "Generation of Use of Nonsupport-Bound Peptide and Peptidomimetic Combinatorial Libraries," *Methods in Enzymology*, (1996) vol. 267, pp. 230-234.
- Bristol, L., et al., "Inhibition of CD26 Enzyme Activity with Pro-boropro Stimulates Rat Granulocyte/Macrophage Colony Formation and Thymocyte Proliferation in Vitro," *Blood*, vol. 85, No. 12 (1995), pp. 3602-3609.
- Ansorge S., et al., "CD26/Dipeptidyl Peptidase IV in Lymphocyte Growth Regulation," *Advances in Medicine and Biology*, (1997), vol. 421, pp. 127-40.
- Reinhold, Dirk, et al., "Inhibitors of Dipeptidyl Peptidase IV (DP IV, CD26) Induces Secretion of Transforming Growth Factor-β1 . . .", *Immunology Letters*, 58(1997), pp. 29-35.

\* cited by examiner



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.